A new SEC filing triggered this report on Thermo Fisher Scientific Inc. (TMO) as of 1 August 2026. No additional briefing disclosures were available in the provided context for the current period.
Thermo Fisher's trailing twelve-month revenue stood at $46.34 billion as of 26 June 2026, reflecting year-over-year growth of 10.49% [SEC 10-Q - TMO - 2026-06-27]. Net income over the same period was $6.98 billion, representing a net margin of 15.07%. Gross margin was recorded at 24.45% and operating margin at 17.58%. Earnings per share grew 9.35% year-over-year. The company held $4.06 billion in cash against total debt of $45.65 billion, producing a notably leveraged balance sheet. The price-to-earnings ratio was reported at 30.89 [SEC 10-Q - TMO - 2026-06-27].
Insider activity over the past 30 days recorded one transaction, directionally a disposal, with a net value of approximately -$226,000 [SEC Form 4 - TMO - 2026-08]. No institutional 13F holdings data was included in the provided context for this reporting period, and therefore no commentary on notable position changes among major filers is presented here.
The prevailing interest rate environment shows the 10-year US Treasury yield at 4.68% and the 2-year yield at 4.23%, producing a normal yield curve spread of 45 basis points [FRED DGS10; FRED DGS2]. This rate configuration is relevant context given TMO's total debt position of $45.65 billion, as prevailing borrowing costs factor into the cost of servicing and refinancing obligations at current market rates.